Insider · CIK 0001856078
Mark Jeffrey DeLong
officer
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 14, 2025, latest Feb 13, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $294k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | $8,153 368 shares | -0% | - | |
| 38Weak | Apellis Pharmaceuticals, Inc. | $73k 3,371 shares | -4% | - | |
| 35Weak | Apellis Pharmaceuticals, Inc. | $26k 1,334 shares | -2% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $39k 1,780 shares | -2% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $10k 363 shares | -0% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $11k 365 shares | -0% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $42k 1,396 shares | -2% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $37k 1,235 shares | -2% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $46k 1,599 shares | -3% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -368 | $22.15 | $8,153 | 114,591 | Feb 13, 2026 |
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +36,606 | $0.00 | $0 | 114,959 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,371 | $21.77 | $73k | 78,353 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,334 | $19.79 | $26k | 81,724 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,780 | $22.19 | $39k | 83,058 | Jan 15, 2026 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Feb 11, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -363 | $28.54 | $10k | 83,945 | Feb 12, 2025 |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -365 | $29.52 | $11k | 84,308 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,396 | $30.43 | $42k | 84,673 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,235 | $29.96 | $37k | 57,561 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +28,508 | $0.00 | $0 | 86,069 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,599 | $28.70 | $46k | 58,796 | Jan 14, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.